Rejection of intestinal allotransplants is driven by memory T helper type 17 immunity and responds to infliximab.

ABSTRACT: Intestinal transplantation (ITx) can be life-saving for patients with advanced intestinal failure experiencing complications of parenteral nutrition. New surgical techniques and conventional immunosuppression have enabled some success, but outcomes post-ITx remain disappointing. Refractory cellular immune responses, immunosuppression-linked infections, and posttransplant malignancies have precluded widespread ITx application. To shed light on the dynamics of ITx allograft rejection and treatment resistance, peripheral blood samples and intestinal allograft biopsies from 51 ITx patients with severe rejection, alongside 37 stable controls, were analyzed using immunohistochemistry, polychromatic flow cytometry, and reverse transcription-PCR. Our findings inform both immunomonitoring and treat

SUBMITTER: Kroemer A 

PROVIDER: S-EPMC8049508 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature